The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis)
Macsai MS
Transactions of the American Ophthalmological Society · 116 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2008-01-01 · Trans Am Ophthalmol Soc · vol. 106 · págs. 336–56
- Editorial
- National Institutes of Health
- Citado
- 161 citas · más que el 97% de estudios similares · 6.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 113 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Ocular Surface and Contact Lens · Fatty Acid Research and Health · Retinal Diseases and Treatments
- Palabras clave
- omega-3 fatty acids, dietary supplementation, blepharitis, meibomian gland dysfunction, meibum, n-6/n-3 ratio, tear film break-up time, ocular surface disease
- MeSH
- meibomian glands, erythrocyte membrane, tears, humans, eyelid diseases, blepharitis, fatty acids, omega-3, linseed oil, fatty acids, omega-6, plant oils, capsules, diet, administration, oral, prospective studies, double-blind method, dietary supplements, middle aged, diet records, female, male, olive oil
1 autor
- Marian Sue Macsai🇺🇸 · autor de correspondenciaNorthwestern University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
Blepharitis and meibomian gland dysfunction (MGD) are common sources of complaints from patients. To evaluate the effect on ocular symptoms, ocular findings, and serum and meibomian gland contents, patients with blepharitis and MGD were prospectively evaluated to determine the effects of dietary supplementation with omega-3 fatty acids.
Methods
In a prospective randomized placebo-controlled masked trial, patients with simple obstructive MGD and blepharitis, who had discontinued all topical medications and tetracyclines, received oral omega-3 dietary supplementation consisting of two 1000-mg capsules 3 times a day. Patients were examined every 3 months for 1 year with the Ocular Surface Disease Index (OSDI) objective clinical measures, including tear production and stability, ocular surface and meibomian gland health, and biochemical plasma, red blood cell (RBC), and meibum evaluation. Primary outcome measures were change in tear breakup time (TBUT), meibum score, and overall OSDI score at 1 year.
Results
At 1 year, the omega-3 group had a 36% and 31% reduction in their omega-6 to omega-3 fatty acid ratios in RBCs and plasma, respectively (P = .3), whereas the placebo group demonstrated no change. At 12 months, the omega-3 group had an improvement in TBUT, OSDI score, and meibum score. Changes in meibum content were observed in the omega-3 group (P = .21); the level of meibum saturated fatty acids decreased.
Conclusions
This trial demonstrated a decrease in the RBC and plasma ratios of omega-6 to omega-3 in patients taking omega-3 dietary supplementation, as compared to controls, and improvements in their overall OSDI score, TBUT, and meibum score. This is the first demonstration of an induced change in the fatty acid saturation content in meibum as a result of dietary supplementation with omega-3 fatty acids.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.